Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?

2026-04-17
Boston Scientific heads into Q1 earnings with strong Cardiovascular momentum and steady MedSurg growth, as estimates point to solid revenue and earnings gains.

Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device Earnings

2026-04-17
We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Boston Scientific Corporation is one of the best healthcare stocks. TheFly reported on April 13 that Mizuho reduced its price target on BSX to $90 from $115 while maintaining an Outperform rating. The adjustment was part of […]

Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

2026-04-17
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

2026-04-17
Faruqi & Faruqi, LLP Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their OptionsIf you purchased or...

Intuitive Surgical Pre-Q1 Analysis: Buy, Hold or Sell the Stock Now?

2026-04-16
Intuitive Surgical faces a key test as earnings near, with strong procedure growth and da Vinci 5 adoption offset by pricing pressure and valuation concerns.

Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026

2026-04-16
Boston Scientific Corporation (NYSE:BSX) is included in our list of the best low-risk high-reward stocks. As part of the firm’s Q1 preview for medical technology and life science tools firms, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $80 from $96 on April 6, 2026, while maintaining an “Outperform” […]

Envoy Medical Appoints Chas McKhann to Board of Directors

2026-04-16
Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.Mr. McKhann

Boston Scientific plans $88.5M R&D expansion in Ireland

2026-04-16
Boston Scientific plans to invest 75 million euros into expanding the site, with a focus on cardiovascular innovation.

BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth

2026-04-16
Key Dates and Disclosure Events Shareholders Need to KnowNEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Boston Scientific Corporation to contact the...

Revisiting Stock Picks Burlington Stores, Boston Scientific, Pinterest

2026-04-16
FEATURE Looking back at previous stock picks can offer a valuable lens into how ideas evolve once they meet real market conditions. Some have played out as expected while others have taken unanticipated paths.